Advances in Monitoring Protocol and Continuous Quality Control for the Optimization of Dendritic -Cell-Derived Exosome (DEX) Immunotherapy

Immunotherapy using dendritic cell-derived exosomes (DEXs) represents an innovative strategy for cancer treatment. While cur-rent clinical monitoring methods, such as RECIST and iRECIST, provide tools for evaluating outcomes through imaging and clin-ical parameters, there remains a gap in comprehensive molecular evaluation of immunotherapy quality. This work reviews exist-ing tools and develops an integrated design that structures these tools into a systematic monitoring protocol to optimize the de-velopment of DEX-based therapies. Methods: The protocol includes flow cytometry for immune characterization, ELISA for cy-tokine profiling (e.g., IFN-γ and IL-12), and Western blotting for exosomal markers (CD63, CD9, and CD81). These molecular tools complement current clinical evaluations, providing comprehensive insights into the quality of DEXs and patient immune responses. Results: Molecular analyses validated the consistency and reproducibility of DEXs through stable expression of exo-somal markers. Furthermore, cytokine profiling revealed significant increases in Th1 responses, including elevated levels of IFN-γ and IL-12, correlated with enhanced T cell activation and tumor cell apoptosis. Conclusions: This work not only reviews existing tools and methodologies but also proposes an original design that organizes and structures these tools into an integral monitor-ing protocol. This system connects clinical and molecular data, optimizing precision, reproducibility, and personalization in DEX-based treatments, establishing a robust foundation to enhance the impact of immunotherapy in oncopathology.